Cargando…
How frequent are vancomycin-resistant enterococci in patients with primary sclerosing cholangitis and ulcerative colitis treated with oral vancomycin?
In patients with primary sclerosing cholangitis (PSC), antimicrobial therapy with oral vancomycin (OV) is increasingly used to prevent progression of the liver disease and control concomitant ulcerative colitis (UC); however, there are concerns regarding the risk of development of vancomycin-resista...
Autores principales: | Shah, Ayesha, Pakneeshan, Sahar, Jones, Michael P, Koloski, Natasha, Callaghan, Gavin, Morrison, Mark, Holtmann, Gerald |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer India
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9715441/ https://www.ncbi.nlm.nih.gov/pubmed/36217097 http://dx.doi.org/10.1007/s12664-022-01286-9 |
Ejemplares similares
-
Oral Vancomycin Therapy in a Child with Primary Sclerosing Cholangitis and Severe Ulcerative Colitis
por: Buness, Cynthia, et al.
Publicado: (2016) -
Microbiome Responses to Vancomycin Treatment in a Child With Primary Sclerosing Cholangitis and Ulcerative Colitis
por: Britto, Savini Lanka, et al.
Publicado: (2021) -
Vancomycin-resistant enterococci: eradication using vancomycin?
por: Van Prehn, J, et al.
Publicado: (2014) -
Oral vancomycin in the treatment of primary sclerosing cholangitis-associated pouchitis
por: Shen, Bo
Publicado: (2021) -
Eradication of Vancomycin-Resistant Enterococci by Combining Phage and Vancomycin
por: Shlezinger, Mor, et al.
Publicado: (2019)